中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 589-593

Application of Mendelian randomization analysis in exploring the etiology of nonalcoholic fatty liver disease

DOI: 10.12449/JCH240325
  • 1.

    Department of Infectious Diseases，Guang’anmen Hospital，Chinese Academy of Chinese Medical Sciences，Beijing 100053，China

  • 2.

    Department of Spleen and Stomach，Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 100700，China

Research funding:

Science and Technology Innovation Project of the Chinese Academy of Traditional Chinese Medicine (CI2021A00801);

Science and Technology Innovation Project of the Chinese Academy of Traditional Chinese Medicine (CI2021A00802)

More Information
  • Corresponding author: LYU Wenliang， lvwenliang@sohu.com （ORCID： 0000-0002-6866-4394）
  • Received Date: 2023-06-28
  • Accepted Date: 2023-07-20
  • Published Date: 2024-03-20
    Abstract
  • Nonalcoholic fatty liver disease （NAFLD） is an abnormal lipid metabolic disorder of the liver characterized by accumulation of a large amount of lipids in the liver， and it is currently the most common liver disease around the world. Mendelian randomization （MR） incorporates genomic data into traditional epidemiological study designs to infer the causal relationship between exposure factors and disease risk. In recent years， MR has been widely used in studies on inference of the etiology of NAFLD. This article systematically summarizes the advances in the application of MR in NAFLD research， so as to provide new ideas for understanding the nature of the disease and scientific interventions.

     

    • FullText(HTML)
  • loading
    • References(48)
  • [1]
    POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
    [2]
    PATERNOSTRO R, TRAUNER M. Current treatment of non-alcoholic fatty liver disease[J]. J Intern Med, 2022, 292( 2): 190- 204. DOI: 10.1111/joim.13531.
    [3]
    TIAN AP, YANG YF. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. J Clin Hepatol, 2023, 39( 3): 491- 497. DOI: 10.3969/j.issn.1001-5256.2023.03.002.

    田爱平, 杨永峰. 非酒精性脂肪性肝病诊断——病理的重要性[J]. 临床肝胆病杂志, 2023, 39( 3): 491- 497. DOI: 10.3969/j.issn.1001-5256.2023.03.002.
    [4]
    LE MH, LE DM, BAEZ TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons[J]. J Hepatol, 2023, 79( 2): 287- 295. DOI: 10.1016/j.jhep.2023.03.040.
    [5]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
    [6]
    MA L, HAO AH, HU XX, et al. Association of fat mass-and obesity-associated gene(FTO)polymorphisms with susceptibility to nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38( 12): 2723- 2727. DOI: 10.3969/j.issn.1001-5256.2022.12.009.

    马磊, 郝岸华, 胡欣欣, 等. 脂肪量和肥胖相关基因多态性与非酒精性脂肪性肝病易感性的关系[J]. 临床肝胆病杂志, 2022, 38( 12): 2723- 2727. DOI: 10.3969/j.issn.1001-5256.2022.12.009.
    [7]
    RICHMOND RC, DAVEY SMITH G. Mendelian randomization: concepts and scope[J]. Cold Spring Harb Perspect Med, 2022, 12( 1): a040501. DOI: 10.1101/cshperspect.a040501.
    [8]
    EMDIN CA, KHERA AV, KATHIRESAN S. Mendelian randomization[J]. JAMA, 2017, 318( 19): 1925- 1926. DOI: 10.1001/jama.2017.17219.
    [9]
    JONES DS, PODOLSKY SH. The history and fate of the gold standard[J]. Lancet, 2015, 385( 9977): 1502- 1503. DOI: 10.1016/S0140-6736(15)60742-5.
    [10]
    GAO X, XUE FZ, HUANG LH, et al. Statistical consensus on Mendelian randomization models and their normative applications[J]. Chin J Health Statistics, 2021, 38( 3): 471- 475. DOI: 10.3969/j.issn.1002-3674.2021.03.042.

    高雪, 薛付忠, 黄丽红, 等. 孟德尔随机化模型及其规范化应用的统计学共识[J]. 中国卫生统计, 2021, 38( 3): 471- 475. DOI: 10.3969/j.issn.1002-3674.2021.03.042.
    [11]
    HE SM, ZHANG Y, PENG LQ, et al. Research progress of propensity score and Mendelian randomization in China[J]. Chin J Dis Control Prev, 2022, 26( 3): 325- 330. DOI: 10.16462/j.cnki.zhjbkz.2022.03.014.

    和思敏, 张雨, 彭刘庆, 等. 倾向性评分与孟德尔随机化国内研究现状[J]. 中华疾病控制杂志, 2022, 26( 3): 325- 330. DOI: 10.16462/j.cnki.zhjbkz.2022.03.014.
    [12]
    HARPER S. A future for observational epidemiology: clarity, credibility, transparency[J]. Am J Epidemiol, 2019, 188( 5): 840- 845. DOI: 10.1093/aje/kwy280.
    [13]
    DAVEY SMITH G, HEMANI G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies[J]. Hum Mol Genet, 2014, 23( R1): R89- R98. DOI: 10.1093/hmg/ddu328.
    [14]
    KATAN MB. Apolipoprotein E isoforms, serum cholesterol, and cancer[J]. Lancet, 1986, 1( 8479): 507- 508. DOI: 10.1016/s0140-6736(86)92972-7.
    [15]
    THOMAS DC, CONTI DV. Commentary: the concept of‘Mendelian Randomization’[J]. Int J Epidemiol, 2004, 33( 1): 21- 25. DOI: 10.1093/ije/dyh048.
    [16]
    YU TQ, XU WT, SU YN, et al. Mendelian randomization: the basic principles, methods and limitations[J]. Chin J Evid-based Med, 2021, 21( 10): 1227- 1234. DOI: 10.7507/1672-2531.202107008.

    于天琦, 徐文涛, 苏雅娜, 等. 孟德尔随机化研究基本原理、方法和局限性[J]. 中国循证医学杂志, 2021, 21( 10): 1227- 1234. DOI: 10.7507/1672-2531.202107008.
    [17]
    CHEN GQ, GU CZ, WANG QL, et al. Advances in Mendelian randomization analysis methods in schizophrenia[J]. J Int Psychiatry, 2022, 49( 3): 385- 387. DOI: 10.13479/j.cnki.jip.2022.03.046.

    陈国庆, 谷传正, 王秋玲, 等. 孟德尔随机化分析方法在精神分裂症中的应用进展[J]. 国际精神病学杂志, 2022, 49( 3): 385- 387. DOI: 10.13479/j.cnki.jip.2022.03.046.
    [18]
    LAURIDSEN BK, STENDER S, KRISTENSEN TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279,013 individuals[J]. Eur Heart J, 2018, 39( 5): 385- 393. DOI: 10.1093/eurheartj/ehx662.
    [19]
    PARK S, LEE S, KIM Y, et al. Causal effects from non-alcoholic fatty liver disease on kidney function: A Mendelian randomization study[J]. Liver Int, 2022, 42( 2): 412- 418. DOI: 10.1111/liv.15118.
    [20]
    LIU Z, SUO C, FAN H, et al. Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases[J]. Metabolism, 2022, 135: 155270. DOI: 10.1016/j.metabol.2022.155270.
    [21]
    REN Z, SIMONS P, WESSELIUS A, et al. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study[J]. Hepatology, 2023, 77( 1): 230- 238. DOI: 10.1002/hep.32534.
    [22]
    PETERMANN-ROCHA F, GRAY SR, FORREST E, et al. Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants[J]. J Hepatol, 2022, 76( 5): 1021- 1029. DOI: 10.1016/j.jhep.2022.01.010.
    [23]
    LIU D, GAO X, PAN XF, et al. The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome[J]. BMC Med, 2023, 21( 1): 62. DOI: 10.1186/s12916-023-02775-0.
    [24]
    LI J, TIAN A, ZHU H, et al. Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19[J]. Clin Gastroenterol Hepatol, 2022, 20( 7): 1553- 1560. e 78. DOI: 10.1016/j.cgh.2022.01.045.
    [25]
    WU M, ZHA M, LV Q, et al. Non-alcoholic fatty liver disease and stroke: A Mendelian randomization study[J]. Eur J Neurol, 2022, 29( 5): 1534- 1537. DOI: 10.1111/ene.15277.
    [26]
    YU Y, YU Y, WANG Y, et al. Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study[J]. Front Endocrinol(Lausanne), 2023, 14: 1156381. DOI: 10.3389/fendo.2023.1156381.
    [27]
    QIU S, CAO P, GUO Y, et al. Exploring the causality between hypothyroidism and non-alcoholic fatty liver: a mendelian randomization study[J]. Front Cell Dev Biol, 2021, 9: 643582. DOI: 10.3389/fcell.2021.643582.
    [28]
    NÄSLUND-KOCH C, BOJESEN SE, GLUUD LL, et al. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals[J]. Front Immunol, 2022, 13: 1022460. DOI: 10.3389/fimmu.2022.1022460.
    [29]
    LIU Y, XU H, ZHAO Z, et al. No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study[J]. Front Microbiol, 2022, 13: 1018322. DOI: 10.3389/fmicb.2022.1018322.
    [30]
    KING SD, VELIGINTI S, BROUWERS M, et al. Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: mendelian randomization[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32( 9): 1265- 1269. DOI: 10.1158/1055-9965.EPI-23-0453.
    [31]
    HARRING M, GOLABI P, PAIK JM, et al. Sarcopenia among patients with nonalcoholic fatty liver disease(nafld) is associated with advanced fibrosis[J]. Clin Gastroenterol Hepatol, 2023, 21( 11): 2876- 2888.e5. DOI: 10.1016/j.cgh.2023.02.013.
    [32]
    ANDERSSON DP, KERR AG, DAHLMAN I, et al. Relationship between a sedentary lifestyle and adipose insulin resistance[J]. Diabetes, 2023, 72( 3): 316- 325. DOI: 10.2337/db22-0612.
    [33]
    XIE J, HUANG H, LIU Z, et al. The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study[J]. Hepatology, 2023, 77( 3): 949- 964. DOI: 10.1002/hep.32728.
    [34]
    LI S, FU Y, LIU Y, et al. Serum uric acid levels and nonalcoholic fatty liver disease: a 2-sample bidirectional mendelian randomization study[J]. J Clin Endocrinol Metab, 2022, 107( 8): e3497, e 3503. DOI: 10.1210/clinem/dgac190.
    [35]
    YUAN S, LARSSON SC. Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21( 2): 398- 405. e 4. DOI: 10.1016/j.cgh.2022.01.021.
    [36]
    CHEN J, RUAN X, SUN Y, et al. Plasma phospholipid arachidonic acid in relation to non-alcoholic fatty liver disease: Mendelian randomization study[J]. Nutrition, 2023, 106: 111910. DOI: 10.1016/j.nut.2022.111910
    [37]
    LI L, HUANG L, YANG A, et al. Causal relationship between complement C3, C4, and nonalcoholic fatty liver disease: bidirectional mendelian randomization analysis[J]. Phenomics, 2021, 1( 5): 211- 221. DOI: 10.1007/s43657-021-00023-0.
    [38]
    ZHANG Y, LIU Z, CHOUDHURY T, et al. Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample Mendelian randomization study[J]. Eur J Nutr, 2021, 60( 4): 1761- 1767. DOI: 10.1007/s00394-020-02369-z.
    [39]
    SUN Z, JI J, ZUO L, et al. Causal relationship between nonalcoholic fatty liver disease and different sleep traits: a bidirectional Mendelian randomized study[J]. Front Endocrinol(Lausanne), 2023, 14: 1159258. DOI: 10.3389/fendo.2023.1159258.
    [40]
    WANG X, LIU Z, LIU W. Does cannabis intake protect against non-alcoholic fatty liver disease? a two-sample mendelian randomization study[J]. Front Genet, 2020, 11: 949. DOI: 10.3389/fgene.2020.00949.
    [41]
    GUO Z, ZHANG T, YUN Z, et al. Assessing the causal relationships between human blood metabolites and the risk of NAFLD: A comprehensive mendelian randomization study[J]. Front Genet, 2023, 14: 1108086. DOI: 10.3389/fgene.2023.1108086.
    [42]
    YUAN S, CHEN J, DAN L, et al. Homocysteine, folate, and nonalcoholic fatty liver disease: a systematic review with meta-analysis and Mendelian randomization investigation[J]. Am J Clin Nutr, 2022, 116( 6): 1595- 1609. DOI: 10.1093/ajcn/nqac285.
    [43]
    TREMBLAY M, PERROT N, GHODSIAN N, et al. Circulating Galectin-3 levels are not associated with nonalcoholic fatty liver disease: a mendelian randomization study[J]. J Clin Endocrinol Metab, 2021, 106( 8): e3178, e 3184. DOI: 10.1210/clinem/dgab144.
    [44]
    KONG L, YE C, WANG Y, et al. Causal effect of lower birthweight on non-alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites[J]. Liver Int, 2023, 43( 4): 829- 839. DOI: 10.1111/liv.15532.
    [45]
    RUAN X, CHEN J, SUN Y, et al. Depression and 24 gastrointestinal diseases: a Mendelian randomization study[J]. Transl Psychiatry, 2023, 13( 1): 146. DOI: 10.1038/s41398-023-02459-6.
    [46]
    TILLMANN T, VAUCHER J, OKBAY A, et al. Education and coronary heart disease: mendelian randomisation study[J]. BMJ(Clinical research ed), 2017, 358: j3542. DOI: 10.1136/bmj.j3542
    [47]
    LI GH, LAM SK, WONG IC, et al. Education attainment, intelligence and COVID-19: A mendelian randomization study[J]. J Clin Med, 2021, 10( 21): 4870. DOI: 10.3390/jcm10214870.
    [48]
    LI Z, ZHANG B, LIU Q, et al. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease[J]. EBioMedicine, 2023, 90: 104543. DOI: 10.1016/j.ebiom.2023.104543.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (456) PDF downloads(90) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return